Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Vancomycin hydrochloride
Drug ID BADD_D02333
Description Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
Indications and Usage A variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci [FDA Label]. Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [L1196].
Marketing Status approved
ATC Code A07AA09; S01AA28; J01XA01
DrugBank ID DB00512
KEGG ID D00926
MeSH ID D014640
PubChem ID 6420023
TTD Drug ID D0B5GS
NDC Product Code 76333-265; 49452-8094; 55500-0004; 16714-699; 17478-741; 23155-858; 23155-859; 25021-151; 0143-9356; 62559-830; 63323-221; 63323-295; 67457-340; 68180-166; 71288-022; 72572-803; 38779-0274; 62991-2522; 16714-517; 25021-157; 52536-104; 0338-3583; 63323-314; 65628-016; 65628-204; 65628-205; 65628-208; 0409-6509; 0409-6510; 0409-6531; 70594-046; 72572-801; 72611-761; 44231-0001; 51927-0069; 0121-0867; 0143-9161; 47781-730; 52536-106; 62559-311; 63323-284; 63629-1971; 68083-143; 68180-167; 0409-4332; 0409-6535; 70436-021; 70860-105; 72572-805; 55150-203; 55150-205; 55150-206; 70436-023; 71288-026; 45932-0009; 45932-0010; 0338-3552; 63323-203; 67457-823; 0404-9965; 68001-406; 68001-407; 0409-5017; 0409-6533; 70594-047; 71288-025; 51927-0199; 16714-247; 52536-107; 52584-332; 0338-3581; 63629-1972; 67457-342; 69238-2261; 70594-045; 70594-048; 52972-0039; 25021-150; 0121-0890; 0143-9152; 0143-9163; 0143-9359; 47781-729; 0338-3582; 65628-015; 67457-339; 68083-569; 70436-022; 76333-264; 42513-0006; 25021-158; 31722-210; 31722-211; 0143-9355; 0143-9357; 0143-9358; 0338-3580; 62559-310; 63629-1970; 65628-206; 67457-705; 67457-824; 68083-570; 0409-3515; 70436-020; 71467-013; 17478-742; 0143-9153; 0143-9162; 52536-108; 55150-204; 66288-7100; 68001-465; 68001-466; 0409-1319; 0409-6534; 70518-3635; 71467-012; 67254-717; 0338-3551; 62559-390; 62559-391; 67457-341; 68083-144; 70860-104; 71288-023; 71288-024; 71467-011; 71467-014; 72611-765; 68254-0006; 16714-309; 0143-9164
UNII 71WO621TJD
Synonyms Vancomycin | Vancomycin Hydrochloride | Hydrochloride, Vancomycin | Vancomycin Sulfate | Sulfate, Vancomycin | Vancomycin-ratiopharm | Vancomycin Hexal | Vancomycine Dakota | AB-Vancomycin | Vanco Azupharma | Diatracin | VANCO-cell | Vanco-saar | Vancocin | Vancocin HCl | Vancomycin Lilly | Vancocine | Vancomicina Abbott | Vancomicina Chiesi | Vancomicina Combino Phar | Vancomicina Norman | Vancomycin Phosphate (1:2) | Vancomycin Phosphate (1:2), Decahydrate
Chemical Information
Molecular Formula C66H76Cl3N9O24
CAS Registry Number 1404-93-9
SMILES CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)N C7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O) O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001--Not Available
Amylase increased13.05.01.009--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Azotaemia20.01.01.001--Not Available
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Chills15.05.03.016; 08.01.09.001--
Deafness04.02.01.001--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Hypotension24.06.03.002--
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Linear IgA disease10.04.02.006; 23.03.01.015--Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Neutropenia01.02.03.004--Not Available
Ototoxicity12.03.01.012; 04.03.01.004--Not Available
Pain08.01.08.004--
Phlebitis24.12.03.004; 12.02.01.002--
Pruritus23.03.12.001--
The 1th Page    1 2    Next   Last    Total 2 Pages